Moshe Szyf

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Moshe Szyf
Scientific career
Fields Epigenetics and Cancer research

Moshe Szyf is a geneticist and James McGill professor of pharmacology and therapeutics at the McGill University, where he also holds a GlaxoSmithKline-CIHR chair in pharmacology.

Szyf's main research interests lie with epigenetics, including behavioral epigenetics as well as cancer research.

Education and career[edit]

Szyf received his Ph.D. from the Hebrew University on basic mechanisms of DNA methylation under supervision of Aharon Razin. Subsequently, he performed postdoctoral work at Harvard Medical School. In 1989, he was appointed as assistant professor in pharmacology and therapeutics at McGill University.[1] In 2016, Moshe Szyf founded Montreal EpiTerapia Inc.



As of October 2013, Moshe Szyf published more than 140 papers in peer-reviewed journals, almost all on epigenetics.[2] He is also on the Editorial Board of the journal Environmental Epigenetics, published by Oxford University Press.[3]

Szyf also holds many patents, all relating to epigenetics-based therapeutics.[2]


  1. ^ Dr. Moshe Szyf, 6th International Conference on Genomics (ICG), 2011
  2. ^ a b Moshe Szyf,
  3. ^ "Environmental Epigenetics Editorial Board". Environmental Epigenetics Editorial Board. Retrieved 17 April 2015. 

External links[edit]